Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090012 · ClinicalTrials.gov registry record · Phase 4
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 340
- Enrollment target
NCT00090012 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 340 participants.
The verdict
NCT00090012, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 340 participants
- Enrollment target
Study Summary
The purposes of this study are to determine: * The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients who are obese or overweight. * The safety of olanzapine as compared to quetiapine.
Interventions
- DRUG Olanzapine
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090012
The ClinicalTrials.gov registry entry for NCT00090012 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00090012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090012 about?
NCT00090012 is a clinical study titled "Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder". The purposes of this study are to determine: * The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients who are obese or overweight. * The safety of olanzapine as compared t...
What is the current status of trial NCT00090012?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 340 participants. The study started on 2004-07. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00090012?
The interventions under investigation include: Olanzapine (DRUG), Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00090012?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.